Achieve Life Sciences, Inc. (ACHV) is a publicly traded Healthcare sector company. As of May 19, 2026, ACHV trades at $4.50 with a market cap of $489.68M and a P/E ratio of -3.61. ACHV moved -6.60% today. Year to date, ACHV is -10.46%; over the trailing twelve months it is +34.44%. Its 52-week range spans $1.84 to $6.15. Analyst consensus is strong buy with an average price target of $13.20. Rallies surfaces ACHV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Achieve Life Sciences Shows 2.5% Nausea Rate in 52-Week Cytisinicline Safety Trial: Achieve Life Sciences’ ORCA-OL trial of 475 adults found no new safety signals over 52 weeks of cytisinicline exposure, with 2.5% reporting nausea and a 5.7% discontinuation rate. This dataset completes the New Drug Application safety package and bolsters cytisinicline’s tolerability profile ahead of its June 20, 2026 PDUFA decision.
| Metric | Value |
|---|---|
| Price | $4.50 |
| Market Cap | $489.68M |
| P/E Ratio | -3.61 |
| EPS | $-1.25 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.15 |
| 52-Week Low | $1.84 |
| Volume | 1.28M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-54.65M |
| Gross Margin | 0.00% |
5 analysts cover ACHV: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.20.